Human Substance P Receptor (NK-1): Organization of the Gene, Chromosome Localization, and Functional Expression of CDNA Clones
Overview
Affiliations
The gene for the human substance P receptor (NK-1) was cloned using cDNA probes made by the polymerase chain reaction from primers based on the rat sequence. The gene spans 45-60 kb and is contained in five exons, with introns interrupting at sites homologous to those in the NK-2 receptor gene. Analysis of restriction digests of genomic DNA from mouse/human cell hybrids indicates the NK-1 receptor is a single-copy gene located on human chromosome 2. Polymerase chain reaction using primers based on the 5' and 3' ends of the coding sequence was used to generate full-length cDNAs from human lung and from IM9 lymphoblast cells. When transfected into COS-7 cells, the NK-1 receptor binds 125I-BHSP with a Kd of 0.35 +/- 0.07 nM and mediates substance P induced phosphatidylinositol metabolism. The receptor is selective for substance P; the relative affinity for neurokinin A and neurokinin B is 100- and 500-fold lower, respectively. Human IM9 lymphoblast cells express relatively high levels of the NK-1 receptor, and Northern blot analysis indicates modulation of mRNA levels by glucocorticoids and growth factors, suggesting that this cell line may be useful as a model for studying the control of NK-1 receptor gene expression.
Serban R, Boldeanu M, Florescu D, Ionescu M, Serbanescu M, Boldeanu L J Clin Med. 2024; 13(18).
PMID: 39337103 PMC: 11432560. DOI: 10.3390/jcm13185616.
The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.
PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.
Hsin L, Fernandopulle N, Ding J, Lumb C, Veldhuis N, Karas J Pharmacol Res Perspect. 2022; 10(4):e00990.
PMID: 35904495 PMC: 9337217. DOI: 10.1002/prp2.990.
Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.
Garcia-Aranda M, Tellez T, McKenna L, Redondo M Cancers (Basel). 2022; 14(9).
PMID: 35565383 PMC: 9102068. DOI: 10.3390/cancers14092255.
Simonetta I, Riolo R, Todaro F, Tuttolomondo A Int J Mol Sci. 2022; 23(6).
PMID: 35328439 PMC: 8955051. DOI: 10.3390/ijms23063018.